# Two-Part Dose-Confirming Study of Pulsed Inhaled Nitric Oxide in Subjects With WHO Group 3 Pulmonary Hypertension Associated With COPD

> **NCT01728220** · PHASE2 · COMPLETED · sponsor: **Bellerophon Pulse Technologies** · enrollment: 159 (actual)

## Conditions studied

- Pulmonary Hypertension
- Chronic Obstructive Pulmonary Disease

## Interventions

- **COMBINATION_PRODUCT:** Inhaled NO delivered via INOpulse DS-C Device
- **COMBINATION_PRODUCT:** Placebo delivered via INOpulse DS-C Device

## Key facts

- **NCT ID:** NCT01728220
- **Lead sponsor:** Bellerophon Pulse Technologies
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2014-06
- **Final completion:** 2014-07
- **Target enrollment:** 159 (ACTUAL)
- **Last updated:** 2023-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01728220

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01728220, "Two-Part Dose-Confirming Study of Pulsed Inhaled Nitric Oxide in Subjects With WHO Group 3 Pulmonary Hypertension Associated With COPD". Retrieved via AI Analytics 2026-09-28 from https://api.ai-analytics.org/clinical/NCT01728220. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*